CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Zapping brain tumors without harming memory: new hope for advanced melanoma
Disease control OngoingThis study looks at whether a focused radiation treatment called stereotactic radiosurgery (SRS) can control melanoma that has spread to more than 3 areas in the brain while also protecting memory and thinking skills. About 49 adults with advanced melanoma and multiple brain tumo…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:03 UTC
-
Triple-Drug cocktail shows promise against tough skin cancers
Disease control OngoingThis study tests a combination of three drugs (dabrafenib, trametinib, and navitoclax) in people with BRAF-mutant melanoma that has spread or cannot be removed by surgery, and in other solid tumors. The goal is to find the best dose and see how well the drugs shrink tumors. About…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:00 UTC
-
Immunotherapy before surgery shows promise for advanced melanoma
Disease control OngoingThis study looks at whether giving the immunotherapy drug pembrolizumab both before and after surgery works better than giving it only after surgery for people with stage III or IV high-risk melanoma. About 313 participants will receive pembrolizumab either before and after surge…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:00 UTC
-
New drug cocktail shows promise for deadly brain tumors in melanoma patients
Disease control OngoingThis study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. The drugs work by blocking tumor growth and helping the immune system attack cancer cells. The trial involves 29 adults with untreated brain metastases and aims to s…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
Experimental combo aims to starve and attack tumors
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Which comes first? landmark trial reveals best sequence for melanoma therapy
Disease control OngoingThis study tested two different sequences of powerful drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New hope for transplant patients with advanced skin cancer: immune drugs may control tumors without losing the kidney
Disease control OngoingThis early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New immunotherapy shows promise in preventing melanoma return
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug pembrolizumab is better than current standard treatments (high-dose interferon or ipilimumab) at preventing melanoma from coming back after surgery. About 1,300 patients with high-risk stage III or IV melanoma that was compl…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo tackles resistant melanoma
Disease control OngoingThis study tests whether adding an experimental drug (tazemetostat) to two standard targeted therapies (dabrafenib and trametinib) can help people with advanced BRAF-mutated melanoma whose cancer has stopped responding to the standard drugs. About 16 adults with metastatic melano…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Melanoma patients may get a break from therapy thanks to PET scans
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. Using PET/CT scans and tumor biopsies as guides, the goal is to see if stopping treatment sooner still keeps the cancer u…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Can your diet boost cancer treatment? fiber study tests Gut-Immune link
Disease control OngoingThis study is testing whether eating a high-fiber diet can change gut bacteria and improve the immune system's response to immunotherapy in people with advanced melanoma. Fifty patients starting standard immunotherapy will be randomly assigned to eat either a high-fiber diet or a…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC